APA (7th ed.) Citation

Fukase, H., Kajioka, T., Oikawa, I., Ikeda, N., & Furuie, H. (2020). AJM300, a novel oral antagonist of α4‐integrin, sustains an increase in circulating lymphocytes: A randomised controlled trial in healthy male subjects. British journal of clinical pharmacology, 86(3), 591-600. https://doi.org/10.1111/bcp.14151

Chicago Style (17th ed.) Citation

Fukase, Hiroyuki, Toshifumi Kajioka, Ichiro Oikawa, Naoki Ikeda, and Hidetoshi Furuie. "AJM300, a Novel Oral Antagonist of α4‐integrin, Sustains an Increase in Circulating Lymphocytes: A Randomised Controlled Trial in Healthy Male Subjects." British Journal of Clinical Pharmacology 86, no. 3 (2020): 591-600. https://doi.org/10.1111/bcp.14151.

MLA (9th ed.) Citation

Fukase, Hiroyuki, et al. "AJM300, a Novel Oral Antagonist of α4‐integrin, Sustains an Increase in Circulating Lymphocytes: A Randomised Controlled Trial in Healthy Male Subjects." British Journal of Clinical Pharmacology, vol. 86, no. 3, 2020, pp. 591-600, https://doi.org/10.1111/bcp.14151.